Advances in Molecular Diagnosis of Tuberculosis-Reference-Cited by-同舟云学术

Advances in Molecular Diagnosis of Tuberculosis

Published:2020-09-22 Issue:10 Volume:58 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

MacLean Emily¹²^ORCID,Kohli Mikashmi¹²^ORCID,Weber Stefan F.³,Suresh Anita⁴,Schumacher Samuel G.⁴^ORCID,Denkinger Claudia M.²³^ORCID,Pai Madhukar¹²⁵^ORCID

Affiliation:

1. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada

2. McGill International TB Centre, McGill University, Montreal, Canada

3. Department of Infectious Diseases, University of Heidelberg, Heidelberg, Germany

4. Foundation for Innovative New Diagnostics, Geneva, Switzerland

5. Manipal McGill Program for Infectious Diseases, Manipal Academy of Higher Education, Manipal, India

Abstract

Molecular tests for tuberculosis (TB) have the potential to help reach the three million people with TB who are undiagnosed or not reported each year and to improve the quality of care TB patients receive by providing accurate, quick results, including rapid drug-susceptibility testing. The World Health Organization (WHO) has recommended the use of molecular nucleic acid amplification tests (NAATs) tests for TB detection instead of smear microscopy, as they are able to detect TB more accurately, particularly in patients with paucibacillary disease and in people living with HIV.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01582-19

Reference85 articles.

1. World Health Organization. 2019. Global tuberculosis report 2019. World Health Organization, Geneva, Switzerland.

2. World Health Organization. 2015. WHO End TB Strategy. World Health Organization, Geneva, Switzerland.

3. Stop TB Partnership. 2020. The potential impact of the COVID-19 response on tuberculosis in high-burden countries: a modelling analysis. Stop TB Partnership, Geneva, Switzerland.

4. Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis

5. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tuberculosis Diagnosis: Current, Ongoing, and Future Approaches;Diseases;2024-09-03

2. Breaking barriers: The potential of nanosystems in antituberculosis therapy;Bioactive Materials;2024-09

3. Tuberculosis Infection and Comorbidities: A Public Health Issue in Baja California, Mexico;Bacteria;2024-08-09

4. Hybrid Polystyrene–Plasmonic Systems as High Binding Density Biosensing Platforms;International Journal of Molecular Sciences;2024-08-07

5. Discordance Between Phenotypic and WGS-Based Drug Susceptibility Testing Results for Some Anti-Tuberculosis Drugs: A Snapshot Study of Paired Mycobacterium tuberculosis Isolates with Small Genetic Distance;Infection and Drug Resistance;2024-08